Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of FF-21101In / FF-21101Y in relapsed/metastatic solid tumors
jRCT2080225141Phase 1Completed
- Sponsor
- PDRadiopharma Inc.
- Start
- Mar 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of FF-21101 in ovarian cancer, biliary cancer and head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by PDRadiopharma Inc. Primary endpoints: Safety and tolerability at 555 MBq/m² FF-21101Y and Organ and tissue radiation dosimetry. Started Mar 2020; status: completed.
02
Drugs
FF-21101
03
Conditions
ovarian cancerbiliary cancerhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2080225141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225141.